Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer’s disease, for instance, damage to specific neurons can alter brainwave rhythms and cause a loss of cognitive functions.
One type of neuron, called inhibitory interneuron, is particularly important for managing brain rhythms. It’s also the research focus of a laboratory led by Jorge Palop, PhD, assistant investigator at the Gladstone Institutes. In a study published in Neuron, Palop and his collaborators uncovered the therapeutic benefits of genetically improving these interneurons and transplanting them into the brain of a mouse model of Alzheimer’s disease.
Interneurons control complex networks between neurons, allowing them to send signals to one another in a harmonized way. You can think of inhibitory interneurons as orchestra conductors. They create rhythms in the brain to instruct the players—excitatory neurons—when to play and when to stop. An imbalance between these two types of neurons creates disharmony and is seen in multiple neurological and psychiatric disorders, including Alzheimer’s disease, epilepsy, schizophrenia, and autism.
A Brain without a Conductor
Palop’s previous studies showed that, in mouse models of Alzheimer’s, the inhibitory interneurons do not work properly. So, the rhythms that organize the excitatory cells are disturbed and fail to function harmoniously, causing an imbalance in brain networks. This, in turn, affects memory formation and can lead to epileptic activity, which is often observed in patients with Alzheimer’s disease.
His team found a way to reengineer inhibitory interneurons to improve their function. They showed that these enhanced interneurons, when transplanted into the abnormal brain of Alzheimer mice, can properly control the activity of excitatory cells and restore brain rhythms.
“We took advantage of the fact that transplanted interneurons can integrate remarkably well into new brain tissues, and that each interneuron can control thousands of excitatory neurons,” said Palop, who is also an assistant professor of neurology at the University of California, San Francisco. “These properties make interneurons a promising therapeutic target for cognitive disorders associated with brain rhythm abnormalities and epileptic activity.”
First, the scientists had to overcome a significant challenge. When they transplanted regular interneurons, they saw no beneficial effects, presumably because Alzheimer’s disease creates a toxic environment in the brain.
The researchers then genetically boosted the activity of inhibitory interneurons by adding a protein called Nav1.1. They discovered that the interneurons with enhanced function were able to overcome the toxic disease environment and restore brain function.
“These optimized neurons are like master conductors,” said Palop. “Even with a declining orchestra, they can restore the rhythms and harmony needed for cognitive functions.”
Conductors Engineered for Alzheimer’s Disease
The findings could eventually lead to the development of new treatment options for patients with Alzheimer’s disease.
“Besides the applications this cell engineering and transplantation approach may find in regenerative medicine, our findings support the broader concept that enhancing the function of interneurons can counteract key aspects of Alzheimer’s disease,” said Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease.
In addition to examining if the cell therapy could be translated from mice to humans, Palop and his team are working to identify potential drugs as an alternative way to enhance the function of inhibitory interneurons.
The Latest on: Alzheimer’s Disease
via Google News
The Latest on: Alzheimer’s Disease
Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?
on July 18, 2018 at 9:23 am
Neurotrope Inc (NASDAQ: NTRP) announced Monday that it has initiated enrollment for a confirmatory Phase 2 study of bryostatin-1 in Alzheimer’s disease. The typically good news of a drug candidate's p... […]
Gates Jumps into Venture Capital Fund Scheme for Early Alzheimer’s Detection
on July 18, 2018 at 8:53 am
Currently, Alzheimer’s diagnoses are more a matter of ruling other medical problems out than definitively confirming the disease. A certain diagnosis only really comes with an autopsy. Even getting cl... […]
ADVERTISING: Advertorial — HOLLY CARLING: Losing your mind: Alzheimer’s and dementia
on July 18, 2018 at 5:00 am
Unfortunately, there are too many that are. There are an estimated 7.5 million Americans that have Alzheimer’s disease. Out of that, about 200,000 are under the age of 65. There is even a new category ... […]
Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging Board
on July 18, 2018 at 3:00 am
Aβ plaque deposits in the brain are a hallmark sign of Alzheimer’s disease, and histological evidence shows that Aβ plaque also accumulates in the retina, the photoreceptor and nerve complex at the re... […]
Neuroscientists Find Alzheimer’s ‘Big Bang’
on July 18, 2018 at 1:54 am
A team of researchers from the University of Texas Southwestern Medical Center, the University of Delaware and Washington University in St. Louis has discovered a ‘Big Bang’ of Alzheimer’s disease — t... […]
Aberdeen goes purple for Alzheimer's disease awareness
on July 17, 2018 at 11:49 pm
Aberdeen will reign purple this week to bring awareness to Alzheimer's disease. "This year is to raise awareness of the disease. We need education in order to grow and take care of our community," sai... […]
Bill Gates jump-starts research for an affordable Alzheimer’s test
on July 17, 2018 at 3:24 pm
Besides a cure, what do those afraid of Alzheimer’s disease need most? According to entrepreneur and philanthropist Bill Gates, a key need is a “reliable, affordable, and accessible” diagnostic test. ... […]
Bill Gates Announces Further Investment In Alzheimer's Research, Taking On Disease Detection
on July 17, 2018 at 10:09 am
Microsoft cofounder Bill Gates revealed more of his plan to invest in Alzheimer's disease research on Tuesday. He along with fellow billionaire Leonard Lauder, the Dolby family, the Charles and Helen ... […]
Test for Alzheimer's disease directly measures synaptic loss
on July 16, 2018 at 1:04 pm
Researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer's disease. The method, which uses PET imaging technology to scan for a specific protein in the b... […]
via Bing News